Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse

作者：Im Annie; Amjad Ali; Agha Mounzer; Raptis Anastasios; Hou Jing Zhou; Farah Rafic; Lim Seah; Sehgal Alison; Dorritie Kathleen A; Redner Robert L; McLaughlin Brian; Shuai Yongli; Duggal Shrina; Boyiadzis Michael^*

来源：Oncology Research, 2016, 24(2): 73-80.

DOI：10.3727/096504016X14586627440156

• Acute myeloid leukemia (AML)
• Relapse
• Prognostic factors
• Mitoxantrone
• Etoposide

Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement of CR in 91 AML patients in first relapse who were treated with the mitoxantrone etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median overall survival for all patients was 7.4 months. The survival of patients who achieved CR and underwent allogeneic hematopoietic cell transplantation (allo-HCT) was higher than those who achieved CR and did not undergo allo-HCT (35.3 months vs. 16.8 months, p=0.057). The median duration of relapse-free survival was 12.7 months in the patients achieving CR. Older age at the time of AML relapse was associated with worse overall survival. The all-cause 4-week mortality rate was 4%, and the all-cause 8-week mortality rate was 13%. The findings of this study underscore the need for newer therapies, especially those that will improve the ability for patients with relapsed AML to achieve CR and to allow them to receive additional therapies.

• 出版日期2016